메뉴 건너뛰기




Volumn 111, Issue 6, 2014, Pages 1241-1248

Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100

(27)  Schneider, B P a   Li, L a   Shen, F a   Miller, K D a   Radovich, M a   O'Neill, A b   Gray, R J b   Lane, D a   Flockhart, D A a   Jiang, G a   Wang, Z a   Lai, D a   Koller, D a   Pratt, J H a   Dang, C T c   Northfelt, D d   Perez, E A e   Shenkier, T f   Cobleigh, M g   Smith, M L h   more..


Author keywords

bevacizumab; breast cancer; hypertension; SNP; SV2C

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NERVE PROTEIN; SV2C PROTEIN, HUMAN;

EID: 84908368251     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.430     Document Type: Article
Times cited : (36)

References (32)
  • 3
    • 81155123190 scopus 로고    scopus 로고
    • RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
    • Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, ONeill V, Rugo HS (2011) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29(32): 4286-4293.
    • (2011) J Clin Oncol , vol.29 , Issue.32 , pp. 4286-4293
    • Brufsky, A.M.1    Hurvitz, S.2    Perez, E.3    Swamy, R.4    Valero, V.5    ONeill, V.6    Rugo, H.S.7
  • 7
    • 0023543690 scopus 로고
    • On the presence of chromaffin cells in the adrenal cortex: Their possible role in adrenocortical function
    • Gallo-Payet N, Pothier P, Isler H (1987) On the presence of chromaffin cells in the adrenal cortex: their possible role in adrenocortical function. Biochem Cell Biol 65(6): 588-592.
    • (1987) Biochem Cell Biol , vol.65 , Issue.6 , pp. 588-592
    • Gallo-Payet, N.1    Pothier, P.2    Isler, H.3
  • 13
    • 0033398955 scopus 로고    scopus 로고
    • SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release
    • Janz R, Goda Y, Geppert M, Missler M, Sudhof TC (1999) SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron 24(4): 1003-1016.
    • (1999) Neuron , vol.24 , Issue.4 , pp. 1003-1016
    • Janz, R.1    Goda, Y.2    Geppert, M.3    Missler, M.4    Sudhof, T.C.5
  • 14
    • 0344761960 scopus 로고    scopus 로고
    • SV2C is a synaptic vesicle protein with an unusually restricted localization: Anatomy of a synaptic vesicle protein family
    • Janz R, Sudhof TC (1999) SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. Neuroscience 94(4): 1279-1290.
    • (1999) Neuroscience , vol.94 , Issue.4 , pp. 1279-1290
    • Janz, R.1    Sudhof, T.C.2
  • 15
    • 84863338437 scopus 로고    scopus 로고
    • Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib
    • Kim JJ, Vaziri SA, Rini BI, Elson P, Garcia JA, Wirka R, Dreicer R, Ganapathi MK, Ganapathi R (2012) Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 118(7): 1946-1954.
    • (2012) Cancer , vol.118 , Issue.7 , pp. 1946-1954
    • Kim, J.J.1    Vaziri, S.A.2    Rini, B.I.3    Elson, P.4    Garcia, J.A.5    Wirka, R.6    Dreicer, R.7    Ganapathi, M.K.8    Ganapathi, R.9
  • 18
    • 1442265950 scopus 로고    scopus 로고
    • Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes
    • Danish Breast Cancer Co-operative Group
    • Olsen KE, Knudsen H, Rasmussen BB, Balslev E, Knoop A, Ejlertsen B, Nielsen KV, Schonau A, Overgaard J. Danish Breast Cancer Co-operative Group (2004) Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 43(1): 35-42.
    • (2004) Acta Oncol , vol.43 , Issue.1 , pp. 35-42
    • Olsen, K.E.1    Knudsen, H.2    Rasmussen, B.B.3    Balslev, E.4    Knoop, A.5    Ejlertsen, B.6    Nielsen, K.V.7    Schonau, A.8    Overgaard, J.9
  • 19
    • 33746512512 scopus 로고    scopus 로고
    • Principal components analysis corrects for stratification in genome-wide association studies
    • Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38(8): 904-909.
    • (2006) Nat Genet , vol.38 , Issue.8 , pp. 904-909
    • Price, A.L.1    Patterson, N.J.2    Plenge, R.M.3    Weinblatt, M.E.4    Shadick, N.A.5    Reich, D.6
  • 20
    • 84881257528 scopus 로고    scopus 로고
    • Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE study
    • Ramsey TL, Liu Q, Massey BW, Brennan MD (2013) Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE study. Schizophr Res 149(1-3): 21-25.
    • (2013) Schizophr Res , vol.149 , Issue.1-3 , pp. 21-25
    • Ramsey, T.L.1    Liu, Q.2    Massey, B.W.3    Brennan, M.D.4
  • 22
    • 79953874259 scopus 로고    scopus 로고
    • RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer
    • Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, OShaughnessy J (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29(10): 1252-1260.
    • (2011) J Clin Oncol , vol.29 , Issue.10 , pp. 1252-1260
    • Robert, N.J.1    Dieras, V.2    Glaspy, J.3    Brufsky, A.M.4    Bondarenko, I.5    Lipatov, O.N.6    Perez, E.A.7    Yardley, D.A.8    Chan, S.Y.9    Zhou, X.10    Phan, S.C.11    Oshaughnessy, J.12
  • 23
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. [Erratum appears in N Engl J Med. 2007;356(3)318]
    • Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. [Erratum appears in N Engl J Med. 2007;356(3):318] N Engl J Med 355(24): 2542-2550.
    • (2006) N Engl J Med , vol.355 , Issue.24 , pp. 2542-2550
    • Sandler, A.1    Gray, R.2    Perry, M.C.3    Brahmer, J.4    Schiller, J.H.5    Dowlati, A.6    Lilenbaum, R.7    Johnson, D.H.8
  • 24
    • 84866849940 scopus 로고    scopus 로고
    • Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment
    • Schneider BP, Shen F, Miller KD (2012) Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment. Lancet Oncol 13(10): e427-e436.
    • (2012) Lancet Oncol , vol.13 , Issue.10 , pp. e427-e436
    • Schneider, B.P.1    Shen, F.2    Miller, K.D.3
  • 25
    • 79959304867 scopus 로고    scopus 로고
    • Anti-vascular endothelial growth factor therapy for breast cancer: Can we pick the winners?
    • Schneider BP, Sledge Jr GW (2011) Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners? J Clin Oncol 29(18): 2444-2447.
    • (2011) J Clin Oncol , vol.29 , Issue.18 , pp. 2444-2447
    • Schneider, B.P.1    Sledge, G.W.2
  • 29
    • 84884401355 scopus 로고    scopus 로고
    • Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: A phase III randomized trial of the Gynecologic Oncology Group
    • abstract 3
    • Tewari KS, Sill M, Long HJ, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ (2013) Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. J Clin Oncol 31(Suppl): abstract 3.
    • (2013) J Clin Oncol , vol.31
    • Tewari, K.S.1    Sill, M.2    Long, H.J.3    Ramondetta, L.M.4    Landrum, L.M.5    Oaknin, A.6    Reid, T.J.7    Leitao, M.M.8    Michael, H.E.9    Monk, B.J.10
  • 30
    • 84938374997 scopus 로고    scopus 로고
    • Randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study
    • abstract 2001
    • Walter Taal Oosterkamp HM, Walenkamp AME, Beerepoot LV, Hanse M, Buter J, Honkoop Boerman f, Dol A (2013) randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study. J Clin Oncol 31(Suppl): abstract 2001.
    • (2013) J Clin Oncol , vol.31
    • Walter Taal Oosterkamp, H.M.1    Walenkamp, A.M.E.2    Beerepoot, L.V.3    Hanse, M.4    Buter, J.5    Honkoop Boermanf Dol, A.6
  • 31
    • 0034908225 scopus 로고    scopus 로고
    • SV2 modulates the size of the readily releasable pool of secretory vesicles
    • Xu T, Bajjalieh SM (2001) SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat Cell Biol 3(8): 691-698.
    • (2001) Nat Cell Biol , vol.3 , Issue.8 , pp. 691-698
    • Xu, T.1    Bajjalieh, S.M.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.